Page last updated: 2024-11-13

abt-450

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

paritaprevir: inhibits HCV NS3 protease [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

paritaprevir : An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID45110509
CHEMBL ID3391662
SCHEMBL ID3069964
MeSH IDM0590129

Synonyms (50)

Synonym
S5404
(2r,6s,12z,13as,14ar,16as)-n-(cyclopropylsulfonyl)-6-{[(5-methylpyrazin-2-yl)carbonyl]amino}-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide
1221573-85-8
viekirax component paritaprevir
paritaprevir [mi]
paritaprevir [inn]
paritaprevir [vandf]
paritaprevir [usan]
paritaprevir [orange book]
paritaprevir [who-dd]
paritaprevir component of viekirax
veruprevir [inn]
1216941-48-8
veruprevir
abt-450
paritaprevir
(2r,6s,12z,13as,14ar,16as)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5h)-carboxamide
abt 450
veruprevir anhydrous
ou2ym37k86 ,
paritaprevir [usan:inn]
unii-ou2ym37k86
abt450
SCHEMBL3069964
CS-5051
(2r,6s,12z,13ar,14ar,16as)-n-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide
AC-33061
HY-12594
AKOS025396424
DB09297
CHEMBL3391662
paritaprevir(abt-450)
(2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
paritaprevir(veruprevir abt-450)
(2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide
EX-A2278
(1s,4r,6s,7z,14s,18r)-n-(cyclopropanesulfonyl)-14-(5-methylpyrazine-2-amido)-2,15-dioxo-18-(phenanthridin-6-yloxy)-3,16-diazatricyclo[14.3.0.0?,?]nonadec-7-ene-4-carboxamide
AS-75348
(1s,4r,6s,7z,14s,18r)-n-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide, n-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2r,6s,12z,13as,14ar,16a
AMY6938
CCG-270449
gtpl11273
veruprevir (deprecated inn)
NCGC00509859-02
(2r,6s,12z,13as,14ar,16as)-n-(cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide
A857160
(1s,4r,6s,7z,14s,18r)-n-(cyclopropanesulfonyl)-14-(5-methylpyrazine-2-amido)-2,15-dioxo-18-(phenanthridin-6-yloxy)-3,16-diazatricyclo[14.3.0.0,4,6]nonadec-7-ene-4-carboxamide
EN300-21959124
DTXSID601027922

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events included eye stye, insomnia, and pain from an infiltrated intravenous line."( Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ, 2015
)
0.42
" Common adverse events included headache, asthenia, pruritus, and diarrhea."( Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Akarca, US; Hall, C; Hézode, C; Lawitz, E; Makara, M; Mobashery, N; Morillas, RM; Pilot-Matias, T; Preotescu, LL; Redman, R; Thuluvath, PJ; Varunok, P; Vilchez, RA, 2015
)
0.42
" Rates of discontinuation due to adverse events (0-1% and 8-11%, respectively, p<0."( Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Arama, V; Campbell, A; Caruntu, FA; Conway, B; Curescu, M; Dalgard, O; Dore, GJ; Fuster, F; Ghesquiere, W; Greenbloom, S; Janczewska, E; Kapoor, M; Knysz, B; Liu, X; Liu, Y; Luo, Y; Mazur, W; Motoc, A; Podsadecki, T; Sasadeusz, J; Shaw, D; Skoien, R; Soza, A; Streinu-Cercel, A; Sullivan, D; Tornai, I, 2016
)
0.43
" OBV/PTV/r+DSV±RBV was associated with a generally better mental and physical health, more favorable tolerability, and lower rates of treatment discontinuation due to adverse events."( Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Arama, V; Campbell, A; Caruntu, FA; Conway, B; Curescu, M; Dalgard, O; Dore, GJ; Fuster, F; Ghesquiere, W; Greenbloom, S; Janczewska, E; Kapoor, M; Knysz, B; Liu, X; Liu, Y; Luo, Y; Mazur, W; Motoc, A; Podsadecki, T; Sasadeusz, J; Shaw, D; Skoien, R; Soza, A; Streinu-Cercel, A; Sullivan, D; Tornai, I, 2016
)
0.43
"To review adverse events (AEs) uniquely associated with DAA therapy across a broad spectrum of patient populations."( Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
Banerjee, D; Reddy, KR, 2016
)
0.43
" Regarding safety, adverse events and serious adverse events were more frequently reported in patients taking concomitant ARAs, though baseline population differences may have played a role."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016
)
0.43
" Safety outcomes were presented by the incidence of adverse events."( Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C, 2016
)
0.43
" Adverse events occurred in 91."( Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C, 2016
)
0.43
" Adverse events occurred in 151 (72."( Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D, 2016
)
0.43
"Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong."( Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF, 2017
)
0.46
" Details of serious adverse events (SAEs) were recorded."( Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017
)
0.46
" Other correlates with adverse events of clinical importance included concomitant ribavirin treatment, sex, race, and presence of cirrhosis, consistent with previous observations."( Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N, 2017
)
0.46
" Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12."( Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017
)
0.46
" The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment."( Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017
)
0.46
" Baseline demographic, clinical and laboratory information, on-treatment biochemical, virological and haematological indices and details on serious adverse events were collected locally."( Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017
)
0.46
" The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported."( Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H, 2017
)
0.46
" Data were analyzed to assess the on-treatment and off-therapy HCV viral load and on-treatment adverse events."( Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC, 2018
)
0.48
"02), while it increased the risk of serious adverse events (p = 0."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A, 2017
)
0.46
" No patients from the G/P Arm prematurely discontinued the study drug or experienced a treatment-emergent serious adverse event (TESAE)."( Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Alves, K; Atarashi, T; Burroughs, M; Chayama, K; Eguchi, Y; Karino, Y; Kato, K; Kawakami, Y; Krishnan, P; Kumada, H; Naganuma, A; Oberoi, RK; Pilot-Matias, TJ; Pugatch, DL; Redman, R; Sato, K; Seike, M; Suzuki, F; Takei, Y; Watanabe, T; Xie, W; Yoshiji, H, 2018
)
0.48
" Safety outcomes were based on the incidence of adverse events."( Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M, 2018
)
0.48
" Adverse events were recorded in 78."( Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M, 2018
)
0.48
"The simplified regimen of OBV/PTV/r+DSV administered for 12 weeks is effective and safe in patients with chronic HCV genotype 1b infection and compensated cirrhosis."( Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M, 2018
)
0.48
" Direct-acting antiviral (DAA) drug regimens are safe and highly effective, allowing administration of treatment also in elderly."( Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A, 2017
)
0.46
" Our aim was to analyze the characteristics associated with the presence of adverse events in patients receiving this antiviral regimen, with ribavirin in cirrhotic patients."( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I,
)
0.13
" We recorded 201 adverse events in 98 (71."( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I,
)
0.13
"We found a high number of adverse events, but most of them were mild or moderate and only one quarter of them required medical intervention."( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I,
)
0.13
"Patients who suffered any adverse event (AE) were 74/240 (30."( Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL, 2018
)
0.48
"Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65."( Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL, 2018
)
0.48
" The other two patients reported only grade 1 adverse effects."( Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M, 2018
)
0.48
"The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective."( Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M, 2018
)
0.48
" However, information about the rate of adverse events (AEs) across different DAA regimens is limited."( Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N, 2018
)
0.48
" Sustained virologic response at post-treatment Week 12 (SVR12), adverse events (AEs) and comedication management were assessed for patients initiating treatment before 1 June 2017."( Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi
Back, D; Bondin, M; Bourgeois, S; Buggisch, P; Charafeddine, M; Crown, E; Curescu, M; Dorr, P; Ferenci, P; Flisiak, R; Kleine, H; Larrey, D; Marra, F; Norris, S, 2019
)
0.51
" However, ribavirin is associated with adverse events that can limit its use."( Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K, 2019
)
0.51
" The patients were evaluated in respect of demographic, clinical and virological data, sustained virologic response (SVR) and adverse events."( [EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA].
Skorokhodova, N; Tsarova, O; Zhyvytsia, D, 2019
)
0.51
" We collected data on on-treatment adverse events (AEs), severe AEs, and laboratory abnormalities."( Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Aoufi-Rabih, S; Dixit, V; Fabrizi, F; Garcia-Agudo, R; Mendizabal, M; Ridruejo, E; Silva, M,
)
0.13
"7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision."( Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019
)
0.51
" Direct-acting antiviral therapy is efficacious and safe even in patients with advanced liver disease and/ or previous virological failure; Model-for-End-Liver-Disease <10 and alanine aminotransferase reduction during therapy were found to be reliable predicting markers of sustained-virological-response."( Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V, 2019
)
0.51
" Rates of adverse events (AEs) in the patients was 59."( Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çelen, MK; Çelik, İ; Demirtürk, N; Ersöz, G; Karakeçili, F; Kınıklı, S; Mıstık, R; Şimşek, F; Türker, N; Turkish Society Of Clinical Microbiology And Infectious Diseases, TSGFVHOT; Ural, O; Yıldız, O; Zararsız, G, 2020
)
0.56
" Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15."( Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L, 2021
)
0.62
" It was associated with high risk IFN-related adverse reactions due to reduced renal clearance of IFN."( Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.
Abd-Elsalam, S; Abo-Amer, YE; Ahmed, R; Badawi, R; El-Abgeegy, M; Elguindy, AMA; Elkadeem, M; Elsergany, HF; Elshweikh, SA; Hawash, N; Mansour, L; Mohmed, AA; Soliman, MY; Soliman, S, 2020
)
0.56
" The most common adverse events were fatigue (12."( Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
Akarca, US; Akarsu, M; Akbulut, S; Akın, M; Aladağ, M; Albayrak, B; Alkım, H; Atalay, R; Balkan, A; Balkan, Y; Çoban, M; Coşar, AM; Danış, N; Değertekin, B; Demir, M; Demircan, M; Dinçer, D; Doğanay, L; Dursun, H; Erarslan, E; Göktürk, HS; Gündüz, F; Güneş, Ş; Gürel, S; Güzelbulut, F; Harputluoğlu, M; İnci, İ; Irak, K; Kaçar, S; Kani, HT; Kartal, A; Kefeli, A; Koklu, H; Mert, A; Nuriyev, K; Özakyol, A; Özdoğan, O; Öztaşkın, S; Sen, İ; Şimşek, H; Soylu, A; Sümer, H; Temel, T; Üçbilek, E; Uğurlu, ÇB; Uyanıkoğlu, A; Vatansever, S; Yalçın, K; Yaras, S; Yıldırım, E, 2020
)
0.56
" Virological response (VR) was measured, as well as the biochemical parameters related to treatment efficacy and adverse events at baseline and after treatment, at 4 (VR4) and 12 (VR12) weeks post-treatment."( Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection.
Ahmed, M; Gomaa, AA; Mansey, AE; Rabea, HM; Wahsh, EA, 2021
)
0.62
" In terms of safety, we monitored the development of adverse reactions, liver cytolysis, cholestasis, and hematologic disorders."( A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A, 2022
)
0.72
" However, a comprehensive review of the adverse event (AE) profile of the DAAs is lacking."( Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
El-Marakby, MG; Sabri, NA; Solayman, MH, 2023
)
0.91
"Hepatitis C virus (HCV) infection is an independent risk factor associated with adverse outcomes in patients with end-stage renal disease (ESRD)."( The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen, R; Wang, X; Xiao, Y; Xiong, Y; Zeng, Y; Zheng, Y, 2023
)
0.91
" Study data that contained patient characteristics, study design, treatment regimens, intention-to-treat sustained virologic response (SVR), and adverse event (AE) data per regimen were extracted into a structured electronic database and analyzed."( The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen, R; Wang, X; Xiao, Y; Xiong, Y; Zeng, Y; Zheng, Y, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma samples were collected through 144 hours after administration for pharmacokinetic assessments."( Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ, 2015
)
0.42
" Co-administration with ritonavir increases paritaprevir exposure and half-life without adversely influencing tolerability."( Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
Awni, WM; Chiu, YL; Dutta, S; Klein, CE; Menon, RM; Podsadecki, TJ, 2016
)
0.43
" A population pharmacokinetic model for paritaprevir was developed using data from formulation, bioavailability, and drug-drug interaction studies that evaluated the pharmacokinetics of paritaprevir (coadministered with ritonavir to enhance exposure) with or without ombitasvir and/or dasabuvir at different paritaprevir dose levels."( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016
)
0.43
" Coadministration of dasabuvir increased paritaprevir bioavailability by 59 %; however, ombitasvir coadministration did not affect the pharmacokinetic profile of paritaprevir."( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016
)
0.43
"Total exposure, measured by area under the plasma concentration-time curve (AUC), was generated for the DAAs, ritonavir, and ribavirin using population pharmacokinetic modeling of data (N = 2093 patients) from 6 Phase 3 studies and 1 Phase 2 study."( Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR, 2017
)
0.46
" The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"A population pharmacokinetic model was developed using tacrolimus dosing and Ctrough data before and during 3D treatment (n = 29)."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"A one-compartment model with first-order absorption adequately described tacrolimus pharmacokinetic profiles during the first 4 weeks of 3D treatment."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"Using data from a phase III clinical trial (GIFT-I) that enrolled Japanese patients with HCV genotype 1b infection, population pharmacokinetic models were developed for the drugs that comprise the 2D regimen: paritaprevir, ombitasvir, and ritonavir."( Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Gopalakrishnan, SM; Khatri, A; Menon, RM; Mensing, S; Polepally, AR, 2017
)
0.46
"Population pharmacokinetic modeling did not reveal any patient-related or clinical parameters that would require dose adjustment of the 2D regimen when used for the treatment of HCV genotype 1b infection in Japanese patients."( Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Gopalakrishnan, SM; Khatri, A; Menon, RM; Mensing, S; Polepally, AR, 2017
)
0.46
"The population pharmacokinetic models for each component of the 3D ± ribavirin regimen (DAAs and ritonavir, n = 2348) and ribavirin (n = 1841) adequately described their respective plasma concentration-time data."( Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S, 2017
)
0.46
" Intensive or sparse pharmacokinetic sampling was performed for assessments of plasma drug concentrations."( Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Alves, K; Ding, B; Luo, Y; Menon, RM; Mobashery, N; Wang, H; Yu, C; Zha, J; Zhao, W, 2019
)
0.51
"Collectively, the results of these pharmacokinetic analyses support the use of the same dose of the 3D regimen for Asian and Western patients."( Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Alves, K; Ding, B; Luo, Y; Menon, RM; Mobashery, N; Wang, H; Yu, C; Zha, J; Zhao, W, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" Thirteen studies were conducted to characterize drug-drug interactions for the 3D regimen of OBV, PTV/r, and DSV and various medications in healthy volunteers to inform dosing recommendations in HCV-infected patients."( Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J, 2015
)
0.42
"Mechanism-based drug-drug interactions were evaluated for gemfibrozil, ketoconazole, carbamazepine, warfarin, omeprazole, digoxin, pravastatin, and rosuvastatin."( Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J, 2015
)
0.42
" Drug-drug interactions were evaluated in healthy volunteers to develop dosing recommendations for HCV-infected subjects."( Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Awni, WM; Badri, PS; Chiu, YL; Dutta, S; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Zha, J, 2016
)
0.43
" A drug-drug interaction (DDI) study was conducted to guide dosing recommendations for UDCA and GCR when coadministered with the 2D regimen."( Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
Alves, K; Badri, PS; Ding, B; Dutta, S; Menon, RM; Redman, R; Rodrigues, L; Uchiyama, N; Zha, J, 2015
)
0.42
" This phase 1, drug-drug interaction, open-label, multiple-dose study enrolled 32 healthy subjects to receive the 3D or 2D regimen in combination with sofosbuvir."( Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Awni, WM; Cohen, D; Ding, B; Dutta, S; King, JR; Menon, RM; Podsadecki, TJ, 2016
)
0.43
" However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen."( Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016
)
0.43
" Drug-drug interaction (DDI) studies of the 3D regimen and commonly used medications were conducted in healthy volunteers to provide information on coadministering these medications with or without dose adjustments."( Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Chiu, YL; Ding, B; Dumas, EO; Khatri, A; King, JR; Menon, RM; Podsadecki, TJ; Polepally, AR; Shuster, DL, 2016
)
0.43
" Drug-drug interactions between 2D (ombitasvir/paritaprevir/ritonavir) or 3D (ombitasvir/paritaprevir/ritonavir and dasabuvir) regimens and omeprazole, a CYP2C19 substrate and acid-reducing agent, were evaluated in 24 healthy volunteers."( Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
Awni, WM; Dutta, S; Hu, B; Menon, RM; Podsadecki, TJ; Polepally, AR, 2016
)
0.43
" These data indicate that the 3-direct-acting-antiviral regimen can be administered with dolutegravir or abacavir plus lamivudine without dose adjustment."( Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W, 2016
)
0.43
" Safe and efficacious antiviral regimens resulting in minimal to no drug-drug interactions (DDIs) with antiretrovirals are needed to ensure that patients coinfected with HCV and the human immunodeficiency virus (HIV) achieve 12-week sustained virologic response rates similar to HCV-monoinfected patients."( Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
King, JR; Menon, RM, 2017
)
0.46
"To assess drug-drug interaction (DDI) potential for the three direct-acting antiviral (3D) regimen of ombitasvir, dasabuvir, and paritaprevir, in vitro studies profiled drug-metabolizing enzyme and transporter interactions."( Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Bow, DAJ; de Morais, SM; Fischer, V; Kavetskaia, O; Liu, J; Nijsen, MJMA; Shebley, M; Sydor, J, 2017
)
0.46
"No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA)."( Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC, 2017
)
0.46
" When a combination therapy with interferon-free, direct-acting antivirals is used in patients post-transplantation, consideration of drug-drug interactions with and monitoring CyA are of vital importance."( Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.
Hashimoto, S; Hayashi, K; Nakagawa, Y; Saito, K; Takahashi, K; Takamura, M; Takeuchi, S; Tanabe, Y; Tasaki, M; Terai, S; Tomita, Y; Yamagiwa, S; Yoshida, T, 2018
)
0.48
" Treatment in the post-transplantation setting may be complicated by significant drug-drug interactions between antiviral agents and standard immune suppressive treatment regimens."( Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C.
Dolman, GE; Gelson, WT; Selby, P, 2018
)
0.48
"Although the combination with PrOD significantly affects the pharmacokinetics of CsA, it is effective and safe with regular monitoring of the CsA blood concentrations and appropriate CsA dose adjustment."( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" ombitasvir and dasabuvir) on paritaprevir bioavailability were included in the model."( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016
)
0.43
" Paritaprevir bioavailability was formulation- and dose-dependent, and increased supraproportionally."( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016
)
0.43
"Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability of antiviral drugs, particularly relevant in patients with advanced liver disease caused by chronic hepatitis C virus (HCV) infection seeking therapy."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016
)
0.43
"Objective Since the majority of direct-acting antivirals (DAAs) that are used in the treatment of hepatitis C virus (HCV) infection are mainly metabolized by CYP3A4, it is hypothesized that inter-individual differences in CYP3A4 activity may be associated with the bioavailability of these agents."( Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI, 2018
)
0.48

Dosage Studied

This phase 2, randomized, open-label study evaluated an IFN- and RBV-free regimen of once-daily ombitasvir (ABT-267), an NS5A inhibitor. Patients received ABT-072 400 mg once daily with weight-based ribavirin 1000-1200 mg/day dosed twice daily for 12 weeks.

ExcerptRelevanceReference
" Patients received ABT-450/r 150/100 mg once daily and ABT-072 400 mg once daily with weight-based ribavirin 1000-1200 mg/day dosed twice daily for 12 weeks."( A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
Bernstein, B; Cohen, DE; Koev, G; Kowdley, KV; Larsen, L; Lawitz, E; Menon, R; Pilot-Matias, T; Podsadecki, T; Poordad, F; Siggelkow, S; Tripathi, R, 2013
)
0.94
"02 log10 was observed at the end of the 3-day dosing period across all doses."( In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.
Cohen, D; Collins, C; Dekhtyar, T; Gaultier, I; Hopkins, T; Irvin, M; Kempf, D; Lu, L; McDaniel, K; Menon, R; Middleton, T; Molla, A; Ng, T; Or, YS; Pilot-Matias, T; Pithawalla, R; Reisch, T; Tripathi, R, 2015
)
0.63
" This phase 2, randomized, open-label study evaluated an IFN- and RBV-free regimen of once-daily ombitasvir (ABT-267), an NS5A inhibitor, plus paritaprevir (ABT-450), an NS3/4A protease inhibitor dosed with ritonavir (paritaprevir/ritonavir), in pegylated IFN/RBV treatment-experienced Japanese patients with hepatitis C virus subtype 1b or genotype 2 infection."( Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
Badri, P; Chayama, K; Kumada, H; Kurosaki, M; Notsumata, K; Pilot-Matias, T; Rodrigues, L; Sato, K; Setze, C; Vilchez, RA, 2015
)
0.61
" Thirteen studies were conducted to characterize drug-drug interactions for the 3D regimen of OBV, PTV/r, and DSV and various medications in healthy volunteers to inform dosing recommendations in HCV-infected patients."( Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J, 2015
)
0.42
" The results suggest that cyclosporine and tacrolimus doses and dosing frequency should be reduced in HCV-infected posttransplant patients being treated with this 3-DAA regimen."( Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
Awni, W; Badri, P; Bernstein, B; Coakley, E; Cohen, D; Ding, B; Dutta, S; Menon, R; Podsadecki, T, 2015
)
0.63
" We examined the efficacy and safety of an all-oral interferon-free regimen of ombitasvir, an NS5A inhibitor, and paritaprevir (ABT-450), an NS3/4A protease inhibitor dosed with ritonavir (ombitasvir plus paritaprevir plus ritonavir), given with or without ribavirin."( Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Asselah, T; Berenguer, M; Fleischer-Stepniewska, K; Hall, C; Hassanein, T; Hézode, C; Marcellin, P; Mobashery, N; Pilot-Matias, T; Pol, S; Reddy, KR; Redman, R; Schnell, G; Vilchez, RA, 2015
)
0.62
" A total of 321 patients without cirrhosis were randomized and dosed with double-blind study drug (106 received double-blind placebo and later received open-label OBV/PTV/r), and 42 patients with cirrhosis were enrolled and dosed with open-label OBV/PTV/r."( Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Burroughs, M; Chayama, K; Ikeda, K; Karino, Y; Kioka, K; Kumada, H; Matsuzaki, Y; Patwardhan, M; Pilot-Matias, T; Redman, R; Rodrigues, L; Sato, K; Setze, C; Suzuki, F; Toyoda, H; Vilchez, RA, 2015
)
0.42
" Where interaction is possible, risk can be mitigated by paying careful attention to concomitant medications, adjusting drug dosage as needed, and monitoring patient response and/or clinical parameters."( Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
Badri, PS; Dutta, S; King, JR; McGovern, BH; Menon, RM; Polepally, AR, 2016
)
0.43
" Drug-drug interactions were evaluated in healthy volunteers to develop dosing recommendations for HCV-infected subjects."( Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Awni, WM; Badri, PS; Chiu, YL; Dutta, S; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Zha, J, 2016
)
0.43
" A drug-drug interaction (DDI) study was conducted to guide dosing recommendations for UDCA and GCR when coadministered with the 2D regimen."( Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
Alves, K; Badri, PS; Ding, B; Dutta, S; Menon, RM; Redman, R; Rodrigues, L; Uchiyama, N; Zha, J, 2015
)
0.42
" To characterize the pharmacokinetics, safety, and tolerability of paritaprevir and determine an optimal dosing regimen for subsequent evaluations, clinical studies were conducted with paritaprevir alone or with ritonavir, a cytochrome P450 3A4 inhibitor anticipated to increase paritaprevir exposure."( Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
Awni, WM; Chiu, YL; Dutta, S; Klein, CE; Menon, RM; Podsadecki, TJ, 2016
)
0.43
"57-fold on repeated dosing compared with the first dose."( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016
)
0.43
"The complex pharmacokinetics of paritaprevir were well described by the model, which can be used as a basis for clinical trial dosing and further evaluations in patients with HCV."( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016
)
0.43
"Among 2,053 patients enrolled and dosed with study drug, 410 (20%) were receiving concomitant ARAs; of these, 308 (15%) were taking concomitant PPIs."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016
)
0.43
" The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"A population pharmacokinetic model was developed using tacrolimus dosing and Ctrough data before and during 3D treatment (n = 29)."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"Observed data for tacrolimus and CSA in liver transplant recipients confirm that the recommended dosing strategies are valid and therapeutic levels of immunosuppression can be maintained during 3D treatment."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"Overall, 24 subjects, six in each of four renal function groups (normal, mild, moderate, and severe), received a single dose of the 3D and 2D regimens in separate dosing periods."( Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Awni, WM; Dutta, S; Khatri, A; Marbury, TC; Menon, RM; Preston, RA; Rodrigues, L; Wang, H, 2017
)
0.46
" In the phase II/III clinical studies, ALT and bilirubin increases were reversible with continued dosing or after treatment cessation."( Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N, 2017
)
0.46
" Patients were randomly assigned (1:1) to receive 25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir once daily, with weight-based ribavirin dosed twice daily for either 12 weeks or 16 weeks."( Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah, T; ElKhashab, M; Feld, JJ; Ferenci, P; Hassanein, T; Hézode, C; Mobashery, N; Moreno, C; Papatheodoridis, G; Pilot-Matias, T; Qaqish, RB; Redman, R; Yu, Y; Zeuzem, S, 2016
)
0.43
" We assessed the efficacy and safety of the two direct-acting antiviral drugs ombitasvir, an NS5A inhibitor, and paritaprevir, an NS3/4A protease inhibitor dosed with ritonavir, plus ribavirin in treatment of chronic HCV infection in Egypt."( Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Allam, N; Asselah, T; Doss, W; Esmat, G; Hall, C; Hassany, M; Mobashery, N; Mohey, MA; Qaqish, RB; Redman, R; Shiha, G; Soliman, R; Waked, I; Yosry, A; Zayed, N, 2016
)
0.43
" Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D."( Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC, 2017
)
0.46
" RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily."( High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018
)
0.48
" We describe the clinical management of ribavirin dosing in hepatitis C virus-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin."( Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z, 2018
)
0.48
"5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment."( Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018
)
0.48
" Plasma trough concentrations, and concentrations at 2, 4, and 6 h after dosing were determined 7 d after the start of treatment."( Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
Ando, H; Fukada, H; Ikejima, K; Miyazaki, A; Morishige, J; Nakadera, E; Okubo, H; Sorin, Y, 2018
)
0.48
"The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily."( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022
)
0.72
" The authors proposed reducing the CsA dosage during PrOD treatment to one-seventh of that of the pre-PrOD treatment of the total daily dose to maintain target CsA levels."( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1649898Absolute bioavailability in human2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1270706Antiviral activity against HCV genotype 1b after 3 days by luciferase reporter assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates.
AID1649893Half life in human2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1467231Inhibition of HCV NS3/4A protease2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
AID1649896Drug excretion in human urine2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1649895Drug excretion in human feces2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1649892Inhibition of HCV NS3/4a protease2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1552078Binding affinity to HCV NS3/4a protease assessed as compound-protein adduct formation per mg protein using radiolabelled compound2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (278)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's235 (84.53)24.3611
2020's43 (15.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.92 (24.57)
Research Supply Index5.92 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials76 (25.85%)5.53%
Reviews42 (14.29%)6.00%
Case Studies32 (10.88%)4.05%
Observational24 (8.16%)0.25%
Other120 (40.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]